Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (47)

I-011Nikolaos Alimpertis

The Finite Absorption Time (F.A.T.) Concept: A new Model Informed Drug Development (MIDD) world is emerging in all phases of drug and generics development

Wednesday 10:30-12:00

I-021Vanessa Baier

A PB-QSP module for ocular applications for the Open Systems Pharmacology – A vancomycin example

Wednesday 10:30-12:00

I-023Pavel Balazki

Predicting Hormonal Contraceptives Drug-Drug-Interactions by leveraging the model database of the Open Systems Pharmacology

Wednesday 10:30-12:00

I-043Salim Bouchene

Population pharmacokinetic analysis of doxecitine and doxribtimine in patients with thymidine kinase 2 deficiency and in healthy volunteers

Wednesday 10:30-12:00

I-052Letizia Carrara

Characterization of the Drug–Drug Interaction potential of vorasidenib via PBPK modelling

Wednesday 10:30-12:00

I-053Adriana Castiñeiras

Population analysis of the clinical pharmacokinetic characteristics of a letrozole long-acting injectable formulation

Wednesday 10:30-12:00

I-055James Chun Yip Chan

Integration of Physics-Informed Neural Networks with Physiologically-based Pharmacokinetic Modelling: A Novel Physics-based Framework for Parameter Discovery

Wednesday 10:30-12:00

I-064Youjung Cho

Population pharmacokinetics of the antifungal immediate-release oral flucytosine to characterize absorption and food effects

Wednesday 10:30-12:00

I-070Susan Cole

Optimisation and evaluation of a physiologically-based model for tacrolimus with mechanistic absorption to inform its use in pregnant and breastfeeding women

Wednesday 10:30-12:00

I-072Bárbara Costa

Drug-Drug Interaction of Lamotrigine and Efavirenz during Pregnancy

Wednesday 10:30-12:00

I-088Wilbert De Witte

Continuous infusion simulations in PBPK and QSP models reveal steady-state properties and rate-limiting steps.

Wednesday 10:30-12:00

I-092Cleo Demeester

Wednesday 10:30-12:00

I-093Abdallah Derbalah

Leveraging PBPK Modelling to Optimize Oligonucleotide Therapeutics: Sustained-Release Strategies for Enhanced Targeting Specificity

Wednesday 10:30-12:00

I-098Ricardo Diaz De Leon Ortega

A PBPK based simulation study to predict potential gastric transit time and permeability driven drug – drug interactions caused by Rybelsus® (semaglutide + SNAC)

Wednesday 10:30-12:00

II-007Angele Fleury

Deconvolution of Gastric Emptying based on interaction between Paracetamol and Liraglutide and its Extrapolation to Comedications using a PBPK Modeling approach

Wednesday 15:30-17:00

II-011Mgambi Gideon Gamba

Investigating the hypothesis of lysosomal trapping of 1-hydroxymidazolam using PBPK modelling

Wednesday 15:30-17:00

II-027Sandra Grañana Castillo

Comparison of Body Weight and Body Surface Area-Based Dosing in Paediatric Population using PBPK modelling

Wednesday 15:30-17:00

II-028Silvia Grandoni

A translational whole-body PBPK modelling framework to support the development of locally acting orally inhaled compounds

Wednesday 15:30-17:00

II-033Mariana Guimaraes

Application of High-Throughput PBPK Modeling to Develop an IVIVE Approach for Oral Permeability

Wednesday 15:30-17:00

II-040Niklas Hartung

Physiologically-based toxicokinetic modelling of aluminium exposure in humans

Wednesday 15:30-17:00

II-052Ravi Kumar Jairam

Physiologically based ocular models for protein therapeutics in rabbits and monkeys

Wednesday 15:30-17:00

II-054Masoud Jamei

Volume of Distribution Covariates That You May not Have Considered!

Wednesday 15:30-17:00

II-063Tobias Kanacher

Physiologically-based pharmacokinetic modeling to support submission of brigimadlin (BI 907828) in dedifferentiated liposarcoma

Wednesday 15:30-17:00

II-077Peter Kilford

Development of network-based PBPK models to enhance the confidence in drug-drug interaction predictions

Wednesday 15:30-17:00

II-083Jakob Kolar

Prediction of sildenafil concentrations in the central nervous system with physiologically based pharmacokinetic modelling

Wednesday 15:30-17:00

II-088Marina Kotsiopoulou

Is flip-flop kinetics a myth?

Wednesday 15:30-17:00

II-102Hyunjung Lee

PBPK Modeling Through Drug-Induced Liver Injury (DILI) Study by Nevirapine and Metabolite Concentrations in Liver Tissue and Blood

Wednesday 15:30-17:00

III-003Dr Chara Litou

A best practice framework for applying physiologically based pharmacokinetic modelling to predict pH-dependent Drug-Drug Interactions

Thursday 9:50-11:45

III-005Feiyan Liu

PBPK Modeling to Recommend Nevirapine Dosing in HIV and HIV-TB Co-infected Patients: Leveraging Enzyme Auto-Induction, Drug Interactions, and Ethnic Variability

Thursday 9:50-11:45

III-008Aurelie Lombard

Across species translation of a novel liver-targeted GalNAc conjugated siRNA using a minimal PBPK/PD approach

Thursday 9:50-11:45

III-009Doortje Esther Lubberts

Evaluating model-based extrapolation for generic long-acting injectable (LAI) products: from single- to multiple-dose studies

Thursday 9:50-11:45

III-010Frederic Lusoli

Development of a PopPK model to predict the oral absorption of Abemaciclib

Thursday 9:50-11:45

III-024Frederico Martins

PHYSIOLOGICALLY BASED BIOPHARMACEUTICS MODELING FOR VIRTUAL BIOEQUIVALENCE ASSESSMENT OF METFORMIN IMMEDIATE AND EXTENDED-RELEASE FORMULATIONS

Thursday 9:50-11:45

III-028Kevin Mcnally

A meta-model-based workflow for massive efficiency gains when applying global sensitivity analysis to PBPK models

Thursday 9:50-11:45

III-054Chen Ning

Physiologically Based Pharmacokinetic (PBPK) Modeling of Atorvastatin and Its Three Relevant Metabolites to predict CYP3A4 and OATP1B1-mediated Drug-Drug-Gene Interactions

Thursday 9:50-11:45

III-060Enoche Oga

Physiologically based pharmacokinetic modeling to predict the pharmacokinetics of metformin, saxagliptin and dapagliflozin in normal and special patient populations

Thursday 9:50-11:45

III-081Sara Peribañez-dominguez

Evaluating Metformin Exposure through PBPK Modeling: A Comparative Study between Cancer Patients and Healthy Subjects

Thursday 9:50-11:45

III-084Zvonimir Petric

Physiologically Based Pharmacokinetic (PBPK) Modeling of Infliximab: Enhancing Treatment Optimization and Clinical Insights in Inflammatory Bowel Disease (IBD)

Thursday 9:50-11:45

III-091Anatoly Pokladyuk

Physiologically-Based Pharmacokinetic Modelling of Niraparib in Special Populations

Thursday 9:50-11:45

III-101Javier Reig-lopez

A Physiologically Based Pharmacokinetic Model of 89Zr-adalimumab in Healthy and Uveitis Diseased Rats

Thursday 9:50-11:45

III-107Marta Rodríguez

A Phisiological-Based Pharmacokinetic model for CD25 Regulatory T cells targeted nanoparticles

Thursday 9:50-11:45

IV-012Ahenk Zeynep Sayin

A Physiologically-Based Computational Model of Bilirubin Metabolism: Integrating Real-World Data for Enhanced Clinical Evidence

Thursday 15:00-16:45

IV-047Elias Toulitsis

Analysis of the absorption processes using the top-down PBFTPK models Impact on the bottom up PBPK modeling work

Thursday 15:00-16:45

IV-049Athanasios Tsekouras

FTPK (Finite Time Pharmacokinetic) software for the analysis of pharmacokinetic data

Thursday 15:00-16:45

IV-068Daan W. Van Valkengoed

Model-based exploration of the P-glycoprotein concentration-activity relationship shows a drug and system dependency: implications for mechanistic PBPK modelling of active transporter activity

Thursday 15:00-16:45

IV-092Kacper Wnuk

Pharmacokinetic Modeling of Ticagrelor in the Presence of Morphine in Healthy Volunteers

Thursday 15:00-16:45

IV-105Javier Zarzoso-Foj

PBBM of ibuprofen enantiomers in tablets: in silico exploration of bioequivalence studies design

Thursday 15:00-16:45